ArticleBMC public health2026
Global disease burden of pulmonary arterial hypertension: patterns and inequality in 1990-2021, with projections to 2035.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Burden dynamics of pulmonary arterial hypertension in China and the G20 aggregate: a comparative analysis based on the global burden of disease study 2023.Annals of medicine · 2026Article
- Multi-target Therapeutic Potential of Baicalin in Respiratory Diseases: Mechanisms and Clinical Prospects.Chinese journal of integrative medicine · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
aimsThis study investigates the global burden of pulmonary arterial hypertension (PAH) from 1990 to 2021, examines its association with sociodemographic factors, and predict the trends from 2020 to 2035.
methodsUtilizing the Global Burden of Disease database, we collected global PAH burden indicators from 1990 to 2021, stratified by age, sex, and Socio-Demographic Index (SDI). Global burden of PAH were assessed using comparative analyses, decomposition analyses, cluster analyses, and health inequality analysis. Bayesian age-period cohort model was used to predict PAH burden from 2020 to 2035.
resultsFrom 1990 to 2021, global PAH age-standardized prevalence rate (ASPR) and age-standardized incidence rate (ASIR) increased by 22.8% and 4.0%, respectively, while the age-standardized mortality rate (ASMR) and disability-adjusted life years rate (ASDR) decreased by 22.9% and 37.6%. The global PAH burden is strongly linked to sociodemographic factors, with notable gender and age disparities, especially among women and the elderly. Decomposition analysis showed population growth drove the global increase in PAH burden, while aging was the main factor in high and upper-middle SDI regions. Frontier analysis and health inequality analysis revealed health improvements but widening disparities. Clustering analysis identified three distinct trajectory groups. By 2035, global ASPR, ASMR, and ASDR are expected to decline, with the largest reduction in ASDR (approximately 31.8%), while ASIR is projected to increase slightly.
conclusionsDespite overall improvements in PAH mortality and disability rates, substantial inequalities persist across regions and demographic groups. Addressing aging challenges and ensuring equitable healthcare distribution will help reduce the burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.